FDA Greenlights Amgen’s Innovative T Cell Therapy for Aggressive Lung Cancer

1. The U.S. Food and Drug Administration (FDA) has granted approval to Amgen's T cell engager therapy, AMG 757, for the treatment of an aggressive form of lung cancer.
2. AMG 757 is a bi-specific T cell engager that targets a specific protein found on the surface of cancer cells, allowing the immune system's T cells to recognize and attack them.
3. The therapy has been approved for the treatment of small cell lung cancer (SCLC), a particularly aggressive form of lung cancer that accounts for about 10-15% of all lung cancer diagnoses.
4. The approval is based on the results of clinical trials that demonstrated the safety and efficacy of AMG 757 in treating SCLC.
5. This marks a significant advancement in the field of immunotherapy and cancer treatment, offering a new option for patients with this aggressive form of lung cancer.
6. Amgen is a leading biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics.
7. The FDA's approval of AMG 757 underscores the agency's commitment to expediting the development and availability of new treatments for serious conditions.